Technologies
PDF


WARF: P160181US02

Improved Influenza B Virus Replication for Vaccine Development


INVENTORS -

Yoshihiro Kawaoka, Gabriele Neumann, Jihui Ping

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in mutations that increase virus titers in cultured cells/embryonated chicken eggs for use in high-growth vaccines produced through reverse genetics.
OVERVIEWThe epidemiology of influenza Type B viruses differs from Type A; influenza B viruses primarily circulate in humans and do not cause pandemics. However, in some seasons the impact of influenza B infections on morbidity and mortality can exceed influenza A.

Over the past few decades, viruses of two influenza B lineages (Victoria and Yamagata) have circulated in humans, and both lineages are now represented in vaccines as recommended by the World Health Organization (WHO). While influenza B virus vaccines for humans have been available for more than 50 years, no systematic efforts have been undertaken to develop high-yield candidates.
THE INVENTIONUW–Madison researchers led by Yoshihiro Kawaoka and Gabriele Neumann have identified growth enhancing mutations that increase the yield of influenza B viruses, potentially enabling more rapid and cost-effective vaccine production.

Virus libraries were generated for each lineage (B/Victoria and B/Yamagata) and passaged in cultured cells to identify several mutations in the ‘internal’ genes of influenza B viruses that confer high-yield in cultured cells and/or embryonated chicken embryos. The use of one or more of these mutations in vaccine virus master strains results in higher viral titers (e.g., 108 PFU/mL or more) in cultured cells and/or embryonated chicken eggs.
APPLICATIONS
  • Influenza B virus vaccine backbones for improved vaccine production
KEY BENEFITS
  • More efficient influenza B virus growth
  • More rapid and cost-effective vaccine production
STAGE OF DEVELOPMENTInfluenza B vaccine virus backbones have been developed that could increase the titers of seasonal vaccines in propagation systems currently used for human applications.
Contact Information
For current licensing status, please contact Jennifer Gottwald at jennifer@warf.org or 608-960-9854.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.